Graves' disease (GD) is associated with HLA-DR3 (DRB1*03) in Caucasians, but the exact amino-acid sequence in the DR b1 chain conferring susceptibility to GD is unknown. Therefore, the aim of our study was to identify the critical sequence among the HLA-DRB1 amino-acid residues occupying the peptide-binding pocket, which conferred susceptibility to GD. We sequenced the HLA-DRB1 locus in 208 Caucasian GD patients and 149 Caucasian controls. Sequence analysis showed an increased frequency of DR b-Arg-74 in GD patients compared to controls (41.8 and 13.4%, respectively; P ¼ 2.3 Â 10 À8 , OR ¼ 4.6). Moreover, subset analyses showed that DR b-Arg-74 was also significantly more frequent in the HLA-DR3 negative GD patients than in controls (7.6 vs 0.8%, P ¼ 0.02, OR ¼ 10.5), suggesting that the association with DR b-Arg-74 is independent of the association with HLA-DR3. Structural modeling studies demonstrated that the change at position 74 from the neutral amino acids Ala or Gln to the positively charged amino-acid Arg significantly modifies the three-dimensional structure of the DR peptide-binding pocket. Our results suggested that structural heterogeneity of the DR b-chain peptidebinding pocket P4 at residue 74 predispose some at risk individuals to GD.
Introduction
Graves' disease (GD) is among the most common human autoimmune diseases with a population prevalence in the United States of approximately 1%.
1,2 GD is characterized clinically by hyperthyroidism, diffuse goiter, and the presence of thyrotropin receptor (TSHR) antibodies. Some patients develop extrathyroidal manifestations, mainly ophthalmopathy and dermopathy (reviewed in Davies 3 ). The pathogenesis of GD is believed to involve a sequence of events that lead to the final clinical phenotype (reviewed in Davies 3 ). The first event is an inborn genetic susceptibility (reviewed in Tomer and Davies 4 ) followed by a second event that is an encounter with an external trigger such as infection (for a review see Tomer and Davies 5 ) or stress. 6 As a result, thyroid-specific T cells become activated and infiltrate the thyroid. The thyroid infiltrating T cells activate B cells to secrete TSHR-stimulating antibodies that induce proliferation of thyrocytes, and production of excess thyroid hormones resulting in hyperthyroidism and goiter (reviewed in Davies 3 ).
The MHC region, encoding the HLA glycoproteins, consists of a complex of genes located on chromosome 6p21. Since the HLA region is highly polymorphic and contains many immune response genes, it was the first candidate genetic region to be studied for association and linkage with GD (reviewed in Tomer and Davies 4 ). Caucasian GD patients have been shown to have an increased frequency of HLA-DR3 (DRB1*03) [7] [8] [9] and HLA-DQA1*0501 haplotypes. 10 The odds ratio (OR) for people with DR3 is about 2-4. 7,9,11 Nevertheless, there are no sequencing data to implicate a specific HLA-DR3 sequence variant. In other autoimmune diseases including Type I diabetes (T1D) 12 and rheumatoid arthritis, 13 there is persuasive evidence that the disease is associated with specific amino-acid sequences of the DRB1 and DQ genes. The same may be true for GD. However, the sequence of the DR b1 chain gene has not been investigated in GD.
The major function of MHC class II molecules (DR, DQ, and DP) in the normal immune response is to bind peptide antigens and present them to T cell receptors. 14 The mechanisms by which certain MHC class II alleles contribute to autoimmunity have been investigated in T1D through a combination of genetic 12, 15 and structural studies. 16 These studies have shown that susceptibility and resistance to T1D are associated with the presence or absence of critical peptide-binding pocket residues, including aspartic acid (Asp) at position 57 of the DQ b chain.
12, 17 We hypothesized that similar mechanisms may explain the association of DR3 with GD. The amino-acid sequences of the DR3 b chain have not been investigated in GD although a large number of variants are recognized (see http://www.anthonynolan.com/HIG/ seq/pep/text/drb_pt.txt). Therefore, the aim of our study was to determine whether specific peptide-binding pocket amino-acid residues were involved in resistance and susceptibility to GD.
Results
Characteristics of the data set We analyzed 208 GD patients (39 males and 169 females). The average age of the patients was 50.3 years (range 21-80). In all, 59% of the patients had documented family history of AITD, 43% had ophthalmopathy, and 71% received radioactive iodine treatment for their disease (Table 1) .
Sequence analyses
We focused our sequencing analysis on potential DR pockets (P 1, 3, 4, 6, 7, and 9) that could be involved in GD susceptibility and protection. 16 . In total, 19 HLA-DR b1 chain amino acids occupy the DR peptide-binding pockets. 16 Of these, three are specific for DR3, that is, they appear in o20% of the published non-DR3 subtype sequences (Asn-37, Lys-71, and Arg-74), and, therefore, could potentially contribute to the susceptibility to GD. According to the published DR3 subtype sequences (http://www.anthonynolan.com/HIG/seq/pep/text/ drb_pt.txt) Asn-37 and Lys-71 are nonpolymorphic (ie they occur in almost all the DR3 subtypes), but Arg-74 is polymorphic among DR3 subtypes (ie some DR3 subtypes have glutamine instead of arginine at position 74 of the b1 chain). In addition, position 74 of the b1 chain is critical for peptide binding to DR3 molecules, 16, 18 and, therefore, we focused our analysis on DRb-Arg74. Sequencing of exon 2 of the DRB1 gene demonstrated a significantly increased frequency of DRb-Arg74 in Caucasian GD patients when compared to matched Caucasian controls (41.8 vs 13.4%; w 2 ¼ 38.8, Table 2 ). In order to examine whether the association of DRb-Arg74 with GD was independent of DR3 we subsetted our patients based on their DR typing. Our analysis demonstrated that nearly all DR3-positive patients and DR3-positive controls were positive for DRb-Arg74. The frequencies of DRb-Arg74 in DR3 positive patients and controls were 100 and 90.5%, respectively (P ¼ NS; Table 3 ). In contrast, among the DR3 negative individuals DRb-Arg74 was significantly more frequent in the GD patients than in the controls (7.6 vs. 0.8%; w 2 ¼ 7.5, P ¼ 0.018, OR ¼ 10.5; Table 4 ), suggesting that the association of GD with DRb-Arg74 was the primary disease association while the association of GD with HLA-DR3 was secondary to the association with DRb-Arg74. 
Structural modeling analysis
The results of sequencing the DRB1 gene showed that susceptibility to GD was associated with the presence of arginine at position 74 of the DRb1 chain. We, therefore, performed structural modeling studies in which we compared the structure of the peptide-binding pocket of HLA-DR3 in the presence of arginine, glutamine, or alanine at position 74 (Figure 1) . The structural modeling analysis demonstrated that the change at position 74, from the common neutral amino acids (Ala or Gln) to a positively charged hydrophilic amino acid (Arg), significantly modified the three-dimensional structure of the P4 peptide-binding pocket (Figure 1) , and thus would be expected to modify the interaction of the DR peptide-binding pocket with different antigenic peptides during presentation to T cells.
Discussion
Sequence variations of HLA class II genes have been shown to play a role in the development of several autoimmune diseases such as T1D 12 and rheumatoid arthritis (reviewed in Winchester 13 ). However, so far HLA-DR sequence analysis has not been performed in GD. This is the first analysis of DRB1 sequences in Graves' patients. As in T1D and rheumatoid arthritis our sequencing results provided evidence for an association between specific DR pocket sequences and GD, suggesting that this may represent a common mechanism in autoimmune diseases that are associated with HLA class II genes.
Our results demonstrated that the presence of arginine at position 74 of the DR b1 chain (DRb-Arg74) was significantly associated with GD. Since most DR3 subtypes contain DRb-Arg74 it was possible that the association of DRb-Arg74 with GD was merely a reflection of the association of DR3 with GD. However, sequence analysis in DR3-negative patients and controls demonstrated that, while DRb-Arg74 was uncommon in them, it was still significantly associated with GD in the DR3 negative individuals. These findings may suggest that the primary association of GD is with DRb-Arg74, while the association with DR3 is secondary to the fact that most DR3 subtypes contain DRb-Arg74. However, due to the small number of DRb-Arg74 positive individuals, this finding could still reflect a random chance event and independent replication is needed to confirm this finding.
Except for arginine the most common amino acids occupying position 74 of the DRb1 chain are alanine and glutamine, and therefore the presence of DRb-Ala74 or DRb-Gln74 could theoretically be protective for GD. Indeed, analysis of electronic sequence databases indicated that DRb-Gln74 is always present on DR7, an allele that was found to be protective for GD in our data set (DR7 was found in 10.1% of our GD patients and in 17.0% of the controls, w 2 ¼ 4.1, P ¼ 0.04), as well as in other Caucasian datasets. 19 This suggests that position 74 of the DRb1 chain is critical for GD development, with DRb-Arg74 conferring susceptibility and DRb-Gln74 conferring protection.
Though HLA-DR3 was consistently found to be associated with GD giving relative risks of 2-4 (reviewed in Tomer and Davies 4 ) linkage studies of HLA in GD have been largely negative. [20] [21] [22] [23] [24] [25] It is difficult to explain why the HLA genes show consistent association with GD but no evidence for linkage. The lack of linkage means that HLA-DR3, as measured, does not have a major contribution to the familial clustering of the disease, while the relatively strong association shows that HLA-DR3 confers a generalized increase in risk for GD in the general population. Indeed, we have recently been able to show that HLA-DR3 was associated with both the sporadic and the familial forms of GD, giving similar relative risks. 26 HLA-DR3 is also associated with several other autoimmune diseases, such as systemic lupus erythematosus (SLE). 27 Recently, much of the focus on human chromosome 6p21 in these diseases has been directed towards nonclass II genes. 28 However, our data suggest that the association of HLA-DR3 with autoimmune disease is not secondary to linkage disequilibrium with nearby genes. It is much more likely that DR structure itself could explain some of the well-established DR3 associations present in these autoimmune diseases as has already been shown in type I diabetes. 29 The mechanism by which DRb-Arg74 confers susceptibility to GD could potentially be similar to the mechanisms by which DQ amino acids confer susceptibility to T1D, namely by influencing the presentation of autoantigens to CD4 þ T cells. 29 The primary autoantigen in GD is the thyrotropin receptor (TSHR). 3 Therefore, presentation of TSHR peptides to class II restricted CD4 þ T cells while bound to HLA-DR b molecules containing arginine at position 74 may be involved in the production of TSHR antibodies in many such patients. Indeed, HLA-DR binding studies have shown higher affinity of HLA-DR3 to TSHR immunodominant peptides than to most TSHR nonimmunodominant peptides. 30 These data may suggest that certain DR sequences influence the binding and presentation of TSHR peptides and this may provide a mechanism by which DRb-Arg74 influences the susceptibility to GD. However, this approach has not yet been applied to specific DR sequences, and further structural and functional studies are needed to confirm this model. Figure 1 The effect of mutations in position b74 of DR3 on the electrostatic potential in the binding groove of the peptide. The three-dimensional structures of DR3 are based on the human DR3-class II associated invariant chain peptide (CLIP) complex (1A6A.pdb, available from www.pdb.org), in which Arg74 was mutated to either Gln or Ala. The electrostatic potentials on the molecular surfaces of DR3 after the removal of the CLIP peptide were generated with Poisson Boltzmann solver implemented in the GRASP (Graphical Representation and Analysis of Surface Properties) program. Surfaces with a negative electrostatic potential are in red, and blue surfaces indicate a positive potential. White surfaces are mostly due to neutral and hydrophobic residues. The peptidebinding pocket is shown with the CLIP peptide superimposed on it. The figures demonstrate that the surface of the peptide-binding pocket is substantially more negative when the larger and positively charged Arg-74 is replaced by the neutral Ala/Gln amino acids.
In summary, we have shown that the presence of arginine at position 74 of the DRb1 chain was significantly associated with GD. Moreover, the association of GD with DRb-Arg74 was independent of the association of GD with HLA-DR3, suggesting a primary role for DRb-Arg74 in the susceptibility to GD. However, only B40% of GD patients are DRb-Arg74 positive (Table 2) . Therefore, structural heterogeneity of the DR b chain at position 74 may be a predisposing factor for GD only in some at risk individuals and other genes must also play important roles in the susceptibility and initiation of GD. 4 Indeed, additional putative GD susceptibility genes have been recently identified, including CTLA-4, [31] [32] [33] [34] CD40, 35, 36 and thyroglobulin. [37] [38] [39] Patients and methods
Patients and controls GD patients. The project was approved by the Mount Sinai School of Medicine institutional review board. In total, 208 Caucasian GD patients were studied, 70 of them were probands from our AITD families, used in our previously published whole genome scan. 25 The diagnosis of GD was established on the basis of: (1) documented clinical and biochemical past or present hyperthyroidism requiring treatment (antithyroid medications, radioactive iodine or surgery); (2) a diffuse goiter; (3) presence of TSH receptor antibodies and/or a diffusely increased 131 I uptake by the thyroid gland on a thyroid scan. TSH receptor antibodies were measured using a radioreceptor assay (Kronus, Boise, ID, USA).
Controls: 149 age-and sex-matched healthy Caucasian volunteers served as controls. All controls had no personal or family history of thyroid disease, and no goiter on exam; they had normal thyroid functions and were negative for thyroid autoantibodies (anti-Tg and anti-TPO antibodies). Thyroid antibodies were measured using a commercial kit (Kronus, Boise, ID, USA).
DNA preparation DNA was extracted from whole blood using the Puregene kit (Gentra Systems, Minneapolis, MN, USA).
HLA typing
For the subset analysis we typed our patients and controls for HLA-DR. Molecular typing of HLA-DR was carried out according to the requirements of The American Society for Histocompatibility. 40 The major alleles of HLA-DR were typed using the technique of group-specific PCR-amplification followed by restriction enzyme digestion as previously described. 41 Direct sequencing of exon 2 of the HLA-DRB1 gene In order to identify the HLA-DR peptide-binding pocket sequences that predispose to GD, we sequenced exon 2 of the HLA-DRB1 gene that encodes the specific amino acids determining the DR specificities. Exon 2 of the HLA-DRB1 gene was sequenced in all GD patients (n ¼ 208) and control subjects (n ¼ 149). Genomic DNA was amplified and sequenced using the following primers:
(1) for DR3 positive individuals: we used previously reported DR3-specific primers: forward primer, CAACCCCGTAGTTGTGTCTG and reverse primer, TGGAGTACTCTACGTCT. 42 Basic Local Alignment Search Tool (BLAST) analysis using the NCBI and Celera databases confirmed the DR3 specificity of these primers. (2) for DR3 negative individuals: we used DRB1-specific primers: forward primer, AGTGTCTTCTCAG GAGGCCG and reverse primer, TCACAGGGACT CAGGCCCCG. BLAST analysis of these primers using the NCBI and Celera databases confirmed their specificity for the DRB1 gene.
PCRs were performed in a 20 ml reaction mixture containing 50 ng genomic DNA; 5 pmol of each primer; PCR buffer containing 50 mmol/l KCl; 10 mmol/l TrisHCl (pH 8.3); 2.25 mmol/l MgCl 2 ; 200 mol/l of each deoxy (d)-ATP, dGTP, dTTP, and dCTP; and 1 U of AmpliTaq DNA polymerase (PE Applied Biosystems, Foster City, CA, USA). Reaction mixtures were heated to 941C for 7 min, then cycled 30 times as follows: 30 s at 941C, 30 s at 551C, and 30 s at 721C. The PCR products were sequenced using the Perkin-Elmer Big Dye DNA sequencing kit (PE Applied Biosystems, Foster City, CA, USA), and separated on an ABI-310 automated sequencer (PE Applied Biosystems).
Sequence alignment and analysis
Sequence alignment analyses were performed using the Sequenchert version 3.1 program (Gene Codes Corporation, Ann Arbor, MI, USA). The known DR3 subtype sequences were obtained from the ImMunoGeneTics project (IMGT)-HLA Informatics Group (HIG) database (http://www.anthonynolan.com/HIG/seq/drb.html).
Statistical analyses
Statistical analyses were performed using the statistical software Epi Info, Version 6.03. (CDC, Atlanta, GA, USA). Case-control association analyses were performed using the w 2 and Fisher's exact tests as indicated. The OR was calculated by the method of Woolf. 43 
Computer modeling
The three-dimensional structures of DR3 were constructed based on the human DR3-class II associated invariant chain peptide (CLIP) complex (1A6A.pdb, available from www.pdb.org). The electrostatic potentials on the molecular surfaces of DR3 after the removal of the CLIP peptide were generated with Poisson Boltzmann solver implemented in the GRASP (Graphical Representation and Analysis of Surface Properties) program. 44 
